Hunter Immunology Ltd. gained a back door listing on the Australian Stock Exchange Wednesday by completing its reverse takeover of publicly quoted probiotics firm Probiomics Ltd.
Promethera Biosciences SA raised €17 million (US$22.7 million) in a Series B round last week to fund the first clinical trials of its allogeneic stem cell therapy for pediatric and adult liver disorders. It also received a further €6.6 million in loan financing from Belgium's Walloon region.
Shares in ReNeuron plc dropped 16 percent Tuesday on news that the stem cell therapy developer is seeking up to £9.4 million (US$14.6 million) in new funding through a combined share placing and open offer.
Promethera Biosciences SA raised €17 million (US$22.7 million) in a Series B round to fund the first clinical trials of its allogeneic stem cell therapy for pediatric and adult liver disorders. It also received a further €6.6 million in loan financing from Belgium's Walloon region.
Shares in NicOx SA surged almost 35 percent last week on news that the company had taken its first concrete step toward becoming a late-stage development and commercial player in opthalmology by entering a cash-and-shares acquisition agreement with Altacor Ltd. that could be worth as much as £19.5 million (US$30.9 million).
Start-up firm ADC Therapeutics Sarl has secured funding commitments of up to $50 million to take forward 10 antibody-drug conjugate programs in oncology, based on conjugate and linker chemistry developed by London-based Spirogen Ltd.
Start-up firm ADC Therapeutics Sarl has secured funding commitments of up to $50 million to take forward 10 antibody-drug conjugate programs in oncology, based on conjugate and linker chemistry developed by London-based Spirogen Ltd.
Shares in NicOx SA surged almost 35 percent Wednesday on news that the company had taken its first concrete step toward becoming a late-stage development and commercial player in opthalmology by entering a cash-and-shares acquisition agreement with Altacor Ltd. that could be worth as much as £19.5 million (US$30.9 million).
DUBLIN, Ireland – Innovation Fund Ireland, the Irish government's initiative to bring top-tier international venture capital funds to Ireland, has landed its first biotechnology investor. Sofinnova Ventures is setting up an office in Dublin and is receiving commitments totaling $37.5 million from the country's public purse.
The Wellcome Trust is setting up a new for-profit investment firm that will have £200 million (US$317 million) on hand to pursue opportunities in health care and in life sciences in the UK and other parts of Europe.
